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Universidade Federal da Bahia, Salvador, Bahia, Brazil, 3 Department of Veterinary Population Medicine,
University of Minnesota, Saint Paul, Minnesota, United States of America, 4 Instituto Nacional de Medicina
Tropical, CONICET, Puerto Iguazu, Misiones, Argentina, 5 Instituto de Ciências da Saúde, Universidade
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Rapid diagnosis tests (RDTs) are easy to carry out, provide fast results, and could poten-
tially guide medical treatment decisions. We investigated the performance of a commercially
available RDT, which simultaneously detects the non-structural 1 (NS1) dengue virus
(DENV) antigen, and IgM and IgG DENV antibodies, using representative serum samples
from individuals in a dengue endemic area in Salvador, Brazil.
Methodology/Principal findings
We evaluated the accuracy of the SD BIOLINE Dengue Duo RDT (Abbott, Santa Clara,
USA; former Alere Inc, Waltham, USA) in a random collection of sera. Samples included
acute-phase sera from 246 laboratory-confirmed dengue cases and 108 non-dengue febrile
patients enrolled in a surveillance study for dengue detection, 73 healthy controls living in
the same surveillance community, and 73 blood donors. RDT accuracy was blindly
assessed based on the combined results for the NS1 and the IgM test components. The
RDT sensitivity was 46.8% (38.6% for the NS1 component and 13.8% for the IgM compo-
nent). Sensitivity was greater for samples obtained from patients with secondary DENV
infections (49.8%) compared to primary infections (31.1%) (P: 0.02) and was also influenced
by the result in the confirmatory dengue diagnostic test, ranging from 39.7% for samples of
cases confirmed by IgM-ELISA seroconversion between paired samples to 90.4% for sam-
ples of cases confirmed by a positive NS1-ELISA. The RDT specificity was 94.4% for non-
dengue febrile patients, 87.7% for the community healthy controls, and 95.9% for the blood
donors.
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Conclusions/Significance
The SD BIOLINE Dengue Duo RDT showed good specificities, but low sensitivity, suggest-
ing that it may be more useful to rule in than to rule out a dengue diagnosis in dengue
endemic regions.
Introduction
Dengue virus (DENV) is estimated to infect up to 390 million people each year, of which 96
million develop clinical disease [1]. Symptomatic DENV infections may cause a wide spectrum
of acute clinical manifestations, from self-limited, mild, and non-specific symptoms, such as
fever, myalgia, and headache, to severe disease evolving with plasma leakage, hemorrhage, and
eventually death [2]. Thus, early diagnosis is critical to guide timely fluid replacement that can
prevent disease complications and death [3].
Several laboratory exams for dengue diagnosis are commercially available, including molec-
ular tests for detection of viral DENV RNA by reverse-transcription polymerase chain reaction
(RT-PCR), enzyme-linked immunosorbent assays (ELISAs) for detection of non-structural 1
(NS1) DENV protein during the viremic phase and detection of DENV IgM antibodies after
the viremic phase, among many others. The choice of which diagnostic method to be used
needs to consider the timing of blood sample collection during the disease course, as well as
other advantages and limitations of each technique, such as accuracy, cost, and the need for
specialized personnel and equipment [4]. Molecular tests and ELISAs are typically time-con-
suming and require laboratory infrastructure not commonly found in outpatient health units.
Thus, they are of limited use for rapid evaluation of patients suspected of dengue and often do
not help guiding medical treatment in such settings.
Rapid tests, which are easy to implement and give fast results, could potentially assist medi-
cal diagnosis and treatment decisions. Yet, they generally present lower sensitivity and speci-
ficity than the other recommended tests, and, therefore, their results have to be interpreted
with caution [2]. There is a wide range of commercially available rapid diagnostic tests (RDTs)
for dengue that focus primarily on the detection of IgM or IgG antibodies, detection of the
NS1 DENV antigen, or in a combination of them. Although previous studies have evaluated
the accuracy of these tests, few assessed the performance of these tests among outpatients from
dengue endemic areas presenting with acute febrile illness, a population who might benefit
greatly from early dengue diagnosis.
Herein, we present results of a retrospective evaluation of the diagnostic performance of a
commercial RDT among febrile outpatients from Salvador, Brazil, a city with endemic DENV
transmission. Among the many dengue RDTs commercially available, we selected to evaluate
the SD BIOLINE Dengue Duo test (Abbott, Santa Clara, USA; former Alere Inc, Waltham,
USA), because of its capability to detect simultaneously the NS1 antigen, and IgM and IgG
DENV antibodies. Furthermore, it has been used in some Brazilian state public health labora-
tories during dengue epidemics.
Methods
Serum sample groups
To evaluate the RDT accuracy we used 500 representative serum samples collected, processed,
and stored following good clinical practices, comprising the following four well characterized
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groups: i) dengue cases confirmed by laboratory reference tests during a surveillance study for
acute febrile illness (AFI) (N: 246 samples); ii) non-dengue AFI controls enrolled in the same
surveillance study (N: 108 samples); iii) presumably healthy individuals living in the same com-
munity where the surveillance study was conducted (healthy community controls) (N: 73 sam-
ples); and iv) blood donors (N: 73 samples) (Fig 1). All the 500 serum samples undergoing RDT
evaluation were stored at -20˚C until use and had never been thawed before. Sample size was
determined based on an average RDT sensitivity and specificity of 85% and 95%, respectively
[5–8], with a minimum precision of 5% and 95% confidence interval. Next, we describe the pro-
cedures for obtaining and selecting the serum samples from each of the evaluated groups.
Samples from dengue and non-dengue AFI patients
Between January 2009 and December 2011, we conducted a community-based enhanced sur-
veillance study aimed to detect DENV infections among AFI patients [9,10]. The AFI surveil-
lance was performed in a public outpatient health unit, located in the Pau da Lima
community, Salvador, Brazil. This area has endemic dengue transmission, with an estimated
incidence of 21 and 70 cases per 10,000 inhabitants in 2009 and 2010, respectively [10]. The
surveillance team prospectively enrolled patients fulfilling the following inclusion criteria: age
of five years or more, reported fever or measured axillary temperature�37.8˚C of up to 21
days of duration, and residence in the community. Enrollment was performed Monday to Fri-
day, from 07h30 to 16h00.
Participants’ blood samples were collected at enrollment (acute-phase sample) and� 15
days post enrollment (convalescent-phase sample), maintained refrigerated at 2–8˚C and
transported on the day of collection to our laboratory at the Gonçalo Moniz Institute for cen-
trifugation. Sera were then stored in aliquots at -20˚C and -70˚C for serological and molecular
testing, respectively. We tested the acute-phase sera samples with DENV NS1- and IgM-E-
LISA, and the convalescent-phase sera with DENV IgM-ELISA (Abbott, Santa Clara, USA; for-
mer Panbio Diagnostics, Brisbane, Australia) according to manufacturer’s instructions.
Patients with a positive result in either of the serological tests and patients enrolled between
February and July 2010, a period when an outbreak of DENV was ongoing in Salvador, had
their acute-phase sample also tested by RT-PCR [11].
We defined as a dengue confirmed case the AFI patients who presented a positive NS1-E-
LISA, an IgM-ELISA seroconversion (a negative result in the acute-phase IgM-ELISA followed
by a positive result in the convalescent-phase IgM-ELISA), or a positive DENV RT-PCR.
Patients presenting only an IgM-ELISA positive result in the acute-phase sample were not con-
sidered as confirmed dengue cases, neither as non-dengue AFI cases because we could not
accurately differentiate those presenting an acute infection from those who had a previous,
recent infection and still maintained DENV IgM antibodies. A non-dengue case was defined
as an AFI patient without any positive laboratory result in the performed tests. Dengue con-
firmed cases also had their acute-phase serum samples tested by IgG-ELISA (Abbott, Santa
Clara, USA; former Panbio Diagnostics, Brisbane, Australia) to determine the type of infection
(primary, defined by a negative result in the IgG-ELISA; versus secondary, defined by a posi-
tive result in the IgG-ELISA).
During the surveillance period, 4,520 AFI patients were enrolled; 571 (12.6%) were classi-
fied as confirmed dengue cases and 3,380 (74.8%) as non-dengue AFI patients (an additional
569 (12.6%) patients tested positive for DENV IgM-ELISA in the acute-phase serum). From
the 416 (72.9%) dengue and 2,168 (64.1%) non-dengue AFI patients with available serum sam-
ple, we randomly selected for this RDT evaluation 246 dengue cases and 108 non-dengue
cases.
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Fig 1. Serum sample selection and SD BIOLINE Dengue Duo testing.
https://doi.org/10.1371/journal.pone.0213301.g001
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Samples from healthy community controls
Serum samples from participants of a household-based random survey, conducted among 5 or
more years of age residents of Pau da Lima, between January and June 2010, were included in
the RDT evaluation study representing a group of presumably healthy community controls
from a dengue endemic region. We randomly selected 73 serum samples from the 2,312 survey
participants for testing by the SD BIOLINE Dengue Duo RDT.
Samples from blood donors
Lastly, serum samples from 73 volunteer blood donors from Salvador metropolitan area were
included as an additional group of negative control. Blood donors’ samples were prospectively
collected in December 2013, after the donators underwent the health triage, which included
age (16 to 69 years), weight (> 50kg), and health restrictions (viral hepatitis, HIV infection,
pregnancy, breastfeeding, risky behavior for blood borne infectious diseases, and fever in the
15 days prior to blood donation).
Blinding
To blind the RDT readers, the 500 selected samples were shuffled and re-identified with
sequential numbers. Readers had no access to the dataset containing the key code of the sam-
ples and did not participate in the re-identification process. Two independent blinded mem-
bers of the study team entered the RDT results into a dataset, which were then validated to
assure data quality. The complete dataset containing all diagnostic results for each patients’
sample were only available for data analysis after all laboratory tests were completed and
inserted in the database (S1 Dataset).
RDT evaluation
The SD BIOLINE Dengue Duo RDT were stored in a closed room with air conditioning before
use. Testing was performed according to the manufacturer’s instruction. Briefly, we added
100 μL of serum in the NS1 component, and 10 μL of serum and 4 drops of the buffer solution
in the IgM and IgG component. Three independent blinded readers, previously trained by a
manufacturer’s representative, interpreted the RDT results in a bright area within 15–20 min-
utes. Each component of the RDT test was considered positive if it showed two positive bands
(the band of the tested component and the internal control band), negative if it presented only
one band (internal control band), and invalid if the internal control band was absent. The
three readers independently recorded each test component reading result. The most frequent
reading result for each test component was considered the final test component result. Each
sample was tested once, unless the RDT presented an invalid result. If so, the test was repeated
according to the same protocol, and the most frequent result between the tree readers in the
repetition test was considered final.
We also evaluated test-to-test reproducibility by randomly selecting 50 samples (10%) and
repeating the testing protocol. In addition, we randomly selected 30 patients of all laboratory-
confirmed dengue cases who had a negative IgM result in the RDT and who had a conva-
lescent-phase serum sample available, and tested the convalescent-phase sample with the RDT.
To investigate false positive results in the RDT, we performed RT-PCR [11] in serum sam-
ples (stored at -70˚C) of all non-dengue AFI controls who had a positive result in either the
NS1- or IgM-RDT component to assure they had been correctly classified as non-dengue
cases. Likewise, to assure that the community and blood donor control groups did not include
an asymptomatic dengue infection during the time of sample collection, we performed NS1-
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and IgM-ELISAs on their -20˚C serum samples. RT-PCR was not performed because these
control groups did not have serum samples stored at -70˚C.
Statistical analysis
We used frequencies and medians plus interquartile ranges (IQR) to describe demographics
and clinical characteristics of the participants from each of the serum sample groups included
in this study and compared them using chi-square or Kruskal-Wallis equality-of-populations
tests. We assessed sensitivity and specificity for the IgM and the NS1 test components, both
separately and in combination, and considered the combined IgM and NS1 reading records as
the final RDT result. The accuracy of the IgG RDT component was not evaluated because
prior studies have shown that the prevalence of IgG antibodies in regions endemic for dengue
can reach 97%, making detection of DENV IgG of limited use for diagnosis in such settings
[12,13].
RDT sensitivity was also calculated by type of dengue infection (primary or secondary),
DENV serotype, number of days of symptoms (0–2, 3–4, and�5), and laboratory confirma-
tion criteria, and differences in the sensitivity according to these patients’ characteristics were
assessed by chi-square or chi-square for trend test. RDT specificity was assessed for each con-
trol group separately. Additionally, sensitivity and specificity for the NS1 and IgM RDT com-
ponents were also assessed against their analogous reference test (NS1- and IgM-ELISAs,
respectively). Confidence intervals at 95% (95% CI) were calculated for all accuracy measure-
ments. Inter-operator agreement between RDT readers and test-to-test reproducibility were
calculated using global agreement and Kappa. Invalid results on the RDT or equivocal results
on the ELISAs were excluded from the analysis. All statistical analysis were done using Stata 14
[14].
Ethics statement
This study was designed, conducted, and reported according to the Evaluation of Diagnostic
Tests for Dengue Guidelines [15] and the STARD (Standards for Reporting of Diagnostic
Accuracy) Guideline (S1 File). The study was approved by the Research Ethics Committee at
the Gonçalo Moniz Institute, Oswaldo Cruz Foundation. All adult AFI patients and control
subjects provided written informed consent. Participants <18 years old who were able to read
provided written assent following written consent from their parent or guardian. All study
data were anonymized before analysis.
Results
Characteristics of the study participants
Of the 246 laboratory-confirmed dengue patients whose samples were selected for this study,
181 (73.6%) were RT-PCR positive, 72 (29.3%) were NS1-ELISA positive, and 151 (61.4%) pre-
sented IgM-ELISA seroconversion between the acute- and convalescent-phase samples. More
than one laboratory criteria for diagnosis occurred for 124 (50.4%) of the dengue cases. Of the
246 dengue confirmed cases, 199 (80.1%) had a secondary infection.
Dengue and non-dengue AFI patients whose samples were selected for this study were simi-
lar regarding sex (42.3% and 44.4% were male, respectively; P = 0.70) and age distribution
(median in years [IQR]: 18 [10–31] and 17 [10–30], respectively; P = 0.23) (Table 1). They also
reported similar frequencies of headache (>80%), prostration (>75%) and myalgia (>70%).
However, the following manifestations were more frequent among dengue cases than among
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non-dengue AFI controls: retro-orbital pain (59.8% vs. 42.6%; P = 0.001), arthralgia (46.3% vs.
32.4%; P = 0.01), and rash (21.5% vs. 12.0%; P = 0.02).
Less than half of the dengue and non-dengue patients had a clinical suspicion recorded in
their medical chart (Table 1). Among those with a recorded clinical suspicion, dengue was sus-
pected for 39.4% of the dengue confirmed cases and for 3.9% of the non-dengue AFI controls
(P<0.001). The most common suspected diagnosis for the non-dengue AFI controls were
upper respiratory tract infections (34.6%).
The community health controls comprised 37.0% males, with a median age of 25 [14–37]
years, and the blood donors comprised 64.4% males, with a median age of 33 [27–41] years
(P<0.001 for sex and age comparison between the four groups, respectively).
Overall RDT sensitivity
Of the 500 tested samples, only 2 (0.4%) needed to be retested to achieve a valid result (both in
the NS1 and IgM/IgG components). Sensitivities for the NS1 and IgM components of the RDT
were 38.6% (95% CI: 32.5–45.0) and 13.8% (95% CI: 3.9–18.8), respectively (Table 2). Consid-
ering a positive result in either the NS1 or the IgM component of the RDT, the combined sen-
sitivity of the RDT was 46.8% (95% CI: 40.4–53.2). The IgG RDT component was positive for
Table 1. Characteristics of laboratory-confirmed dengue cases and of non-dengue acute febrile illness cases whose sera were included in the panel for the SD BIO-
LINE Dengue Duo rapid test evaluation.
Characteristics Dengue AFI (n = 246) Non-dengue AFI (n = 108) p-valuea
N (%) or median (IQR)
Age in years 18 (10–31) 17 (10–30) 0.23
Male sex 104 (42.3) 48 (44.4) 0.73
Days of symptoms at enrollment 2 (2–4) 3 (1–4) 0.42
Clinical manifestations
Headache 214 (87.0) 91 (84.3) 0.50
Prostration 195 (79.3) 82 (75.9) 0.48
Myalgia 187 (76.0) 77 (71.3) 0.35
Retro-orbital pain 147 (59.8) 46 (42.6) 0.003
Arthralgia 114 (46.3) 35 (32.4) 0.02
Rash 53 (21.5) 13 (12.0) 0.04
Vomiting 74 (30.1) 30 (27.8) 0.71
Clinical diagnoses recorded at medical chart
None 144 (58.5) 56 (51.9) 0.25
At least one clinical diagnosis b 102 (41.5) 52 (48.1)
Dengue 39 (39.4) 2 (3.9) <0.001
Upper respiratory tract infections 16 (16.2) 18 (34.6) 0.01
Undetermined viral disease 28 (28.3) 7 (13.5) 0.04
Gastrointestinal tract infections 4 (4.0) 2 (3.9) 1.00
Urinary tract infections 2 (2.0) 1 (1.9) 1.00
Pneumoniae 1 (1.0) 1 (1.9) 1.00
Sinusitis 0 (0) 3 (5.8) 0.04
Leptospirosis 3 (3.0) 2 (3.9) 1.00
Tonsillitis 10 (10.1) 12 (23.1) 0.05
AFI, Acute febrile illness.
a Wilcoxon (Mann-Whitney) rank-sum test or Fisher’s exact test.
b Some patients had more than one clinical diagnosis recorded in their medical chart.
https://doi.org/10.1371/journal.pone.0213301.t001
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64 (26.0%) of the 246 dengue cases, all of them with a secondary infection defined by a positive
IgG-ELISA in the acute-phase sample (32.2% of the 199 secondary dengue infections detected
by the IgG-ELISA).
RDT sensitivity according to characteristics of the dengue confirmed cases
Sub-analyses of the RDT sensitivity revealed that specific differences among the dengue con-
firmed cases, such as the type of infection, the number of days with symptoms at the time of
sample collection, and the laboratory result in the reference tests might influence the RDT per-
formance (Table 2). In contrast, the overall RDT sensitivity did not significantly differ accord-
ing to the infecting DENV serotype (P = 0.18).
Sensitivity for the NS1 and the IgM RDT components combined were significantly higher
among secondary DENV infections than among primary DENV infections (P = 0.02)
(Table 2). In addition, as expected, the NS1 RDT sensitivity decreased (P = 0.07 for trend),
while the IgM RDT sensitivity improved with the increase in the number of days of symptoms
at acute-phase sample collection (P<0.001 for trend). Consequently, the overall RDT sensitiv-
ity (considering both components) declined from 47.9% when the test was used in the first 4
days after disease onset to 36.7% when used in patients with�5 days of symptoms, but this dif-
ference was not statistically significant (P = 0.25).
The NS1 RDT component had good sensitivity (90.4%) when the dengue case had a positive
NS1-ELISA as one of the confirmation criteria, but performance was poor for dengue cases
confirmed by RT-PCR (50.8%) and IgM-ELISA seroconversion (34.4%) (Table 2). In contrast,
the IgM RDT component presented low sensitivity regardless of the dengue confirmation cri-
teria used and its sensitivity was low (36.9%) even for the 65 dengue confirmed cases who had
a positive IgM-ELISA in the acute-phase sample.
RDT sensitivity in a subset of convalescent-phase samples
We randomly selected 30 of the 212 dengue confirmed patients with a negative IgM-RDT
result in the acute-phase serum and an available convalescent-phase serum in order to test the
convalescent-phase sample by the RDT. We found that none of the 30 convalescent-phase
samples tested were positive by the NS1 RDT component, but 13 (43.3%) were positive by the
IgM component. Of note, the IgM-ELISA was positive in 28 (93.3%) of the 30 convalescent-
Table 3. Specificity of the NS1 and IgM SD BIOLINE Dengue Duo Rapid Diagnostic Test (RDT) components
according to control group.
RDT component evaluated
by control group
No. tested samples No. negative samples Specificity % (95% CI)
Non-dengue AFI
NS1 RDT 108 106 98.2 (93.5–99.8)
IgM RDT 108 104 96.3 (90.8–99.0)
NS1 or IgM RDT 108 102 94.4 (88.3–97.9)
Community’s healthy controls
NS1 RDT 73 71 97.3 (90.5–99.7)
IgM RDT 73 66 90.4 (81.2–96.1)
NS1 or IgM RDT 73 64 87.7 (77.9–94.2)
Blood donors
NS1 RDT 73 72 98.6 (92.6–100.0)
IgM RDT 73 71 97.3 (90.5–99.7)
NS1 or IgM RDT 73 70 95.9 (88.5–99.1)
https://doi.org/10.1371/journal.pone.0213301.t003
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phase sera samples. As 10 (33.3%) of these 30 patients had the NS1 RDT component positive
in the acute-phase sample, altogether, the paired sera evaluation resulted in a RDT sensitivity
of 76.7% (23 out of 30).
RDT specificity
The combined NS1 and IgM RDT specificity were 94.4% for non-dengue AFI patients, 87.7%
for community healthy controls, and 95.9% for blood donor controls (Table 3). Specificity of
the NS1 component ranged from 97.3% to 98.6% (98.0% for the combined control groups)
and was higher than the specificity for the IgM-component, which ranged from 90.4% to
97.3% (94.9% for the combined control groups), but the difference was not statistically signifi-
cant when we considered the three control groups combined (P = 0.06).
Acute-phase samples of all non-dengue AFI patients with a positive result in either the
NS1- or IgM-RDT component were tested by DENV RT-PCR and presented negative results.
Of the 9 community control samples with positive results in the RDT, 2 were also positive
when tested by IgM-ELISA and none were positive by NS1-ELISA. None of the 3 blood donor
control samples with positive results in the RDT were positive by NS1- or IgM-ELISA.
Reproducibility
Inter-operator agreement in visual interpretation of the test ranged from 96.0% to 98.8%
(kappa ranging 0.87–0.96) for the NS1-RDT component, 94.4% to 97.8% (kappa 0.63–088) for
the IgM-RDT, and 87.0% to 94.0% (kappa 0.67–0.86) for the IgG-RDT. Test-to-test reproduc-
ibility with 50 randomly selected samples revealed a global agreement of 94.0% (kappa = 0.81)
for the NS1-RDT component, 96.0% (kappa = 0.81) for the IgM-RDT component, and 86.0%
(kappa = 0.68) for the IgG component.
Discussion
In this study, we evaluated the diagnostic performance of the commercial SD BIOLINE Den-
gue Duo RDT among febrile patients from an outpatient health unit in a dengue endemic
region, as well as among different control groups. Although the test presented good levels of
specificity (88%– 96%), its overall sensitivity (combining positivity in either the NS1 or the
IgM component) was not satisfactory (46.8%). This low sensitivity was associated with a sub-
optimal performance of both the NS1 and the IgM components of the test in detecting dengue
cases early and late in the course of the disease, respectively.
Previous evaluations of this RDT found much greater sensitivities, ranging between 75.5–
97.5% [5–8,16–20]. The diversity in patients’ clinical characteristics, frequency of primary and
secondary infections, infecting DENV serotypes, and reference dengue diagnostic methods
used between our study and other investigations may explain the observed differences in the
measured sensitivities [15,16,21]. In our study, dengue confirmed cases were outpatients with
mild disease. In contrast, the majority of the other studies were conducted on hospitalized
patients, which usually manifest greater disease severity and duration, consequently influenc-
ing the intensity of inflammatory and immune response [22–24]. Yet, a previous evaluation of
this RDT in Cambodia, enrolling children hospitalized due to a febrile illness of no clear
source, showed an overall low sensitivity (57.8%) [21]. An even lower sensitivity (30.8%) was
observed during a prospective cohort study that followed school-aged children to detect febrile
episodes in Colombia [21,25].
The sensitivity of this RDT according to the type of infection remains controversial. Some
studies have found higher sensitivity among patients with primary DENV infections [7,26,27],
while others have observed no significant difference according to the infection type [17,18,28],
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or have shown high sensitivity among patients with secondary DENV infections [6][8]. Those
who found higher sensitivity among primary infection patients have suggested that DENV IgG
antibodies, present in secondary infections, may form immune complexes with viral antigens
reducing the sensitivity of the NS1 component of the RDT [18]. In addition, the lower IgM
production in secondary dengue infections would reduce the sensitivity of the IgM component
of the test [29]. We, however, found a higher sensitivity among secondary infections, regard-
less of the RDT component being evaluated. This could be partly explained because patients
with secondary DENV infections boost a faster DENV-specific IgM immune response that
improve the test sensitivity.
Our small number of confirmed dengue cases with�5 days of symptoms underpowered
our capacity to detect statistical differences in the RDT sensitivity according to disease dura-
tion. However, our findings suggest that the test does not achieve sufficient performance levels
even when applied later on the course of disease. First, because the sensitivity of the IgM com-
ponent of the test remained low (<30%) for acute-phase samples collected from patients with
�5 days of symptoms. Second, because when we evaluated the RDT performance on conva-
lescent-phase samples for a subset of 30 dengue-confirmed patients with negative IgM RDT
results in the acute-phase sample, we only found 13 positive samples (none positive by the NS1
component and 13 positive by the IgM component), indicating a convalescent-phase sensitiv-
ity for the RDT test of only 43.3%. Nevertheless, combining the results of the acute- and conva-
lescent-phase samples for these 30 dengue patients, we obtained a sensitivity of 76.7%. Thus,
paired sample testing may be used to confirm a dengue diagnosis when the RDT returns a neg-
ative result in the acute-phase sample.
We defined a dengue case by a combination of RT-PCR, NS1-ELISA or IgM-ELISA sero-
conversion to ensure high confidence that the AFI patients really had an ongoing dengue
infection and to provide the diverse laboratory scenario of dengue confirmed cases. In addi-
tion, our dengue confirmed cases were randomly selected among all dengue cases prospec-
tively identified during a surveillance study to detect dengue cases among AFI patients. Thus,
the proportion of samples fulfilling the different confirmation criteria should partially repre-
sent the scenario encountered among dengue outpatients from endemic regions. This choice
turned out to be correct, because we found that the accuracy of the RDT was largely influenced
by the reference diagnostic method used. As an example, when considering only the samples
from dengue confirmed patients with positive results in the NS1-ELISA, we found that the
NS1 component of the RDT achieved a high sensitivity (90.4%). However, the overall sensitiv-
ity for the NS1 RDT component was of 38.6% because only 73 (29.7%) of our 246 confirmed
dengue patients had a positive result in the NS1 ELISA. As we did in our evaluation, it is criti-
cal that studies testing the accuracy of diagnostic methods use serum samples from representa-
tive cases instead of a convenient serum sample collection.
The specificity of the RDT was high, regardless of the control group. However, the commu-
nity controls presented a lower RDT specificity (87.7%) compared to other groups. This may
be explained by recent dengue infections in this randomly selected representatives from a
region of endemic dengue transmission [10], as IgM for dengue may persist for up to 2 or 3
months [29]. Of note, the 7 samples presenting a false positive RDT result in the IgM compo-
nent were also positive in the IgM-ELISA. The visual interpretation of RDT results showed
good to excellent agreements between independent readers, while test-to-test reproducibility
was considered very good for the NS1 and the IgM RDT components, and good for the IgG
component [30].
Some limitations of this study need to be acknowledged. First, samples were not tested for
other flaviviruses, such as yellow fever (YFV) and Zika (ZIKV) viruses, which have antigenic
similarities to DENV and could potentially produce serological cross-reactions. However,
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YFV transmission did not occur in Salvador before 2016, when an epizootic outbreak was first
detected [31]. In addition, the large ZIKV epidemics that recently reached Brazil, having the
northeast region as the epicenter, only started in late 2014 and, in Salvador, it peaked in May
of 2015, with over 17,000 reported cases [32]. According to phylogenetic studies, ZIKV was
introduced to Brazil in late 2012 or early 2013 [33,34]. Thus, although possible, it is unlikely
that the subjects providing blood samples for our study have had a ZIKV infection because the
AFI samples from dengue and non-dengue cases were collected between 2009 and 2011, com-
munity control samples were collected in 2010, and only the blood donor samples were
obtained in 2013. Second, RT-PCR for dengue diagnosis was only systematically performed on
AFI patients presenting a positive result for dengue in the NS1- or IgM-ELISA. However, to
verify for potential misclassification bias among the non-dengue AFI control group, we tested
their acute-phase serum sample by RT-PCR whenever the RDT gave a positive result and none
of the tested samples were RT-PCR positive. Lastly, we did not include AFI patients with only
a positive IgM ELISA result in the acute-phase sample among the confirmed dengue patients
to ensure greater precision in our case definition, since a positive IgM ELISA in the acute-
phase sample might represent either an active or a previous, recent infection. Although this
approach might have influenced the RDT accuracy, when we evaluated the RDT performance
among the subset of samples from patients who fulfilled our dengue case definition and who
also had a positive IgM ELISA in the acute-phase sample, we still observed a suboptimal sensi-
tivity of 56.9%.
In conclusion, this RDT showed high specificity, indicating that AFI patients with a positive
result in either in the NS1 or the IgM component of the test can be confidently considered
dengue cases. However, it presented a low sensitivity, and, therefore, AFI patients with a nega-
tive RDT result should not have a dengue diagnosis discarded. In this case, performing addi-
tional diagnostic tests and/or obtaining a convalescent-phase blood sample to test might help
achieve a more accurate result. Prospective studies in outpatient health units, testing fresh
blood instead of stored sera, are needed to evaluate the accuracy of this RDT during point-of-
care use, as well as to determine its impact in proper disease clinical management.
Supporting information
S1 File. STARD (Standards for Reporting of Diagnostic Accuracy) checklist for the report-
ing of studies of diagnostic accuracy.
(DOCX)
S1 Dataset. Clinical and laboratory data of the study participants.
(XLS)
Acknowledgments
We would like to thank the technical staff who participated in study data collection and in
sample processing. We would also like to thank the indispensable contributions to accomplish
this work provided by the São Marcos Emergency Center staff, especially from Aurélio Nei
and Celeste Moura; of the Pau da Lima Health District, Salvador Secretariat of Health; Pau da
Lima community leaders and resident associations; and the State Blood Donation Center
located in Salvador.
Author Contributions
Conceptualization: Mariana Kikuti, Guilherme S. Ribeiro.
Accuracy of the SD BIOLINE Dengue Duo rapid diagnosis test
PLOS ONE | https://doi.org/10.1371/journal.pone.0213301 March 6, 2019 12 / 15
Data curation: Mariana Kikuti, Guilherme S. Ribeiro.
Formal analysis: Mariana Kikuti.
Funding acquisition: Mitermayer G. Reis, Guilherme S. Ribeiro.
Investigation: Mariana Kikuti, Jaqueline S. Cruz, Moreno S. Rodrigues, Aline S. Tavares, Igor
A. D. Paploski, Monaise M. O. Silva, Laura B. Tauro, Greice A. O. F. Silva, Gúbio S. Cam-
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Guilherme S. Ribeiro.
References
1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and
burden of dengue. Nature. 2013; 496: 504–507. https://doi.org/10.1038/nature12060 PMID: 23563266
2. WHO. Dengue: Guidelines for diagnosis, treatment, prevention and control. Geneva: World Health
Organization; 2009.
3. Teixeira MDG, Costa MDCN, Barreto ML, Mota E. Dengue and dengue hemorrhagic fever epidemics in
Brazil: what research is needed based on trends, surveillance, and control experiences? Dengue e
febre hemorrágica do dengue no Brasil: que tipo de pesquisas a sua tendência, vigilância e experiên-
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